The Commission approved, subject to commitments, the acquisition of the Swedish medical technology company Gambo by its US rival healthcare company Baxter. Both companies are active in the area of continuous renal replacement therapy (“CRRT”) equipment and consumables which serve patients suffering from acute kidney failure. Both companies operate in the European Economic Area (“EEA”). The Commission’s investigation revealed that the proposed acquisition, as initially notified, would have combined two of the leading suppliers of CRRT equipment and consumables leading to very high market shares in a significant number of Member States. To address the Commission’s concerns, Baxter proposed to divest its global CRRT business as well as to undertake to set up a line for the production of fluids used in CRRT at a location of the purchaser’s choice in the EEA or Switzerland. In view of these commitments, the Commission concluded that the proposed acquisition will not significantly impede effective competition in the EEA or in any substantial part thereof. Source:Commission Press Release 22/07/2013